OT? Another deadly drug approved for Crohn's

[Guest guest]

By the by, my cousin's wife contracted Crohn's immediately after a

college MMR vax and cured herself with a live-food, dairy-free diet.

She didn't realize that the MMR had been the culprit until her son

almost died from the vaccine as an infant and she put two and two

together.

Tysabri was originally approved for MS, was removed from the market

for causing multifocal leukoencephalopathy, or PML. What would that

do to a child already suffering brain and nerve damage from vaccines?

FDA OKs Tysabri to fight Crohn's disease By MATTHEW PERRONE, AP

Business Writer

Mon Jan 14, 6:44 PM ET

WASHINGTON - Tysabri, a treatment for multiple sclerosis made by

Biogen Idec Inc. and Elan Corp., received regulatory approval on

Monday for use among patients with a severe intestinal disorder.

The Food and Drug Administration approved Tysabri for use in patients

with moderate to severe Crohn's disease who don't respond to more

conventional drugs, such as Abbott Laboratories' Humira.

The approval represents a comeback for Tysabri, which was temporarily

pulled from the market in 2005 after three patients using the drug

developed a rare nervous system disorder called multifocal

leukoencephalopathy, or PML.

FDA allowed the drug back on the market the following year, but only

under a restricted distribution program. The drug is used by more

than 12,000 multiple sclerosis patients in the U.S., according to

Biogen, with no new reports of the fatal disorder.

Government officials said Tuesday Crohn's disease patients would have

to enroll in a similar distribution program for Tysabri. Patients

must undergo an educational program on the drug's risks and can only

receive the injectable drug from a select number of registered

physicians.

About 500,000 people in the U.S. have Crohn's, which usually causes

diarrhea, fever and internal bleeding. There is no known cure.

Cambridge, Massachusetts-based Biogen said distribution of Tysabri

for Crohn's patients will begin by the end of next month. Company

representatives said a year's supply of drug will likely be priced at

$29,000 (euro19,470).

Last week, Biogen management said it hoped to expand Tysabri's market

to 100,000 patients by 2010. But some analysts, including BMO Capital

Markets Zhang, note the drug's safety risks could limit its

distribution.

The drug is expected to compete with Remicade in the U.S., the

leading Crohn's treatment made by and .

[Guest guest]

Crohn's is a paraTB infection (see www.crohns.org)

But don't tell Big Pharma

KP Stoller, MD

President, International Hyperbaric Medical Assoc

Medical Director, Hyperbaric Medical Center of New Mexico

www.hbotnm.com

_____________________________________________________________

Click to learn how to make millions with hedge funds.

http://thirdpartyoffers.netzero.net/TGL2221/fc/Ioyw6i4tFKgupDBUQKbxCQBxDdCHKxW36\

LZoUwmI1ziSg4UjPztRA4/

[Guest guest]

I can't tell Big Pharma. They won't listen. Wonder why?

>

> Crohn's is a paraTB infection (see www.crohns.org)

>

> But don't tell Big Pharma

>

>

> KP Stoller, MD

> President, International Hyperbaric Medical Assoc

> Medical Director, Hyperbaric Medical Center of New Mexico

> www.hbotnm.com

>

>

>

>

> _____________________________________________________________

> Click to learn how to make millions with hedge funds.

>

http://thirdpartyoffers.netzero.net/TGL2221/fc/Ioyw6i4tFKgupDBUQKbxCQB

xDdCHKxW36LZoUwmI1ziSg4UjPztRA4/

>

[Guest guest]

Tysabri was a god-send to many patients suffering from Crohns that

either found Remicade and Humira ineffective or who became intolerant

to both of them. It's also worth knowing that no patient on Tysabri

alone got PML, it was only two patients who were on both Tysabri and

Avonex. The third patient's records have been changed to reflect

Remicade as the cause of PML.

Just as important, Tysabri is by far the most effective MS treatment

that exists today. Patients who were previously confined to wheel

chairs are starting to walk because Tysabri is preventing further

demylenation and allowing the body to heal itself. Did you know that

Crohns patients often suffer RA, and while on Tysabri their RA

subsided?

So, Tysabri can help with demylenation issues, RA and Crohns. These

are all issues that effect many of our children. This drug has

enormous potential to help ASD children.

FWIW

Jeff

>

> By the by, my cousin's wife contracted Crohn's immediately after a

> college MMR vax and cured herself with a live-food, dairy-free

diet.

> She didn't realize that the MMR had been the culprit until her son

> almost died from the vaccine as an infant and she put two and two

> together.

>

> Tysabri was originally approved for MS, was removed from the

market

> for causing multifocal leukoencephalopathy, or PML. What would that

> do to a child already suffering brain and nerve damage from

vaccines?

>

>

> FDA OKs Tysabri to fight Crohn's disease By MATTHEW PERRONE, AP

> Business Writer

> Mon Jan 14, 6:44 PM ET

>

>

> WASHINGTON - Tysabri, a treatment for multiple sclerosis made by

> Biogen Idec Inc. and Elan Corp., received regulatory approval on

> Monday for use among patients with a severe intestinal disorder.

>

> The Food and Drug Administration approved Tysabri for use in

patients

> with moderate to severe Crohn's disease who don't respond to more

> conventional drugs, such as Abbott Laboratories' Humira.

>

> The approval represents a comeback for Tysabri, which was

temporarily

> pulled from the market in 2005 after three patients using the drug

> developed a rare nervous system disorder called multifocal

> leukoencephalopathy, or PML.

>

> FDA allowed the drug back on the market the following year, but

only

> under a restricted distribution program. The drug is used by more

> than 12,000 multiple sclerosis patients in the U.S., according to

> Biogen, with no new reports of the fatal disorder.

>

> Government officials said Tuesday Crohn's disease patients would

have

> to enroll in a similar distribution program for Tysabri. Patients

> must undergo an educational program on the drug's risks and can

only

> receive the injectable drug from a select number of registered

> physicians.

>

> About 500,000 people in the U.S. have Crohn's, which usually causes

> diarrhea, fever and internal bleeding. There is no known cure.

>

> Cambridge, Massachusetts-based Biogen said distribution of Tysabri

> for Crohn's patients will begin by the end of next month. Company

> representatives said a year's supply of drug will likely be priced

at

> $29,000 (euro19,470).

>

> Last week, Biogen management said it hoped to expand Tysabri's

market

> to 100,000 patients by 2010. But some analysts, including BMO

Capital

> Markets Zhang, note the drug's safety risks could limit its

> distribution.

>

> The drug is expected to compete with Remicade in the U.S., the

> leading Crohn's treatment made by and .

>

[Guest guest]

The most effective treatment for MS is hyperbaric oxygen, but since no one makes $2000 an injection from it, there is no money to promote it or fight Big Pharma with their suppression.

HBOT is the primary therapy for MS in the UK by MS patients for MS patients with over 60 charity centres and 100 chambers through out Ireland, Scotland and England.

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

Since those who want to know understand Crohn's is an infection, it is absolute insanity to treat an infection with an immune suppressive drug. Again...go to www.crohns.org, don't take my word for it, or do an internet search on mycoplasma and Crohns.

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$KP Stoller, MDPresident, International Hyperbaric Medical AssocMedical Director, Hyperbaric Medical Center of New Mexicowww.hbotnm.com-- "j__stone" <etiguy@...> wrote:

Tysabri was a god-send to many patients suffering from Crohns that either found Remicade and Humira ineffective or who became intolerant to both of them. It's also worth knowing that no patient on Tysabri alone got PML, it was only two patients who were on both Tysabri and Avonex. The third patient's records have been changed to reflect Remicade as the cause of PML.Just as important, Tysabri is by far the most effective MS treatment that exists today. Patients who were previously confined to wheel chairs are starting to walk because Tysabri is preventing further demylenation and allowing the body to heal itself. Did you know that Crohns patients often suffer RA, and while on Tysabri their RA subsided?So, Tysabri can help with demylenation issues, RA and Crohns. These are all issues that effect many of our children. This drug has enormous potential to help ASD children.FWIWJeff>> By the by, my cousin's wife contracted Crohn's immediately after a > college MMR vax and cured herself with a live-food, dairy-free diet. > She didn't realize that the MMR had been the culprit until her son > almost died from the vaccine as an infant and she put two and two > together.> > Tysabri was originally approved for MS, was removed from the market > for causing multifocal leukoencephalopathy, or PML. What would that > do to a child already suffering brain and nerve damage from vaccines?> > > FDA OKs Tysabri to fight Crohn's disease By MATTHEW PERRONE, AP > Business Writer > Mon Jan 14, 6:44 PM ET> > > WASHINGTON - Tysabri, a treatment for multiple sclerosis made by > Biogen Idec Inc. and Elan Corp., received regulatory approval on > Monday for use among patients with a severe intestinal disorder. > > The Food and Drug Administration approved Tysabri for use in patients > with moderate to severe Crohn's disease who don't respond to more > conventional drugs, such as Abbott Laboratories' Humira.> > The approval represents a comeback for Tysabri, which was temporarily > pulled from the market in 2005 after three patients using the drug > developed a rare nervous system disorder called multifocal > leukoencephalopathy, or PML.> > FDA allowed the drug back on the market the following year, but only > under a restricted distribution program. The drug is used by more > than 12,000 multiple sclerosis patients in the U.S., according to > Biogen, with no new reports of the fatal disorder.> > Government officials said Tuesday Crohn's disease patients would have > to enroll in a similar distribution program for Tysabri. Patients > must undergo an educational program on the drug's risks and can only > receive the injectable drug from a select number of registered > physicians.> > About 500,000 people in the U.S. have Crohn's, which usually causes > diarrhea, fever and internal bleeding. There is no known cure.> > Cambridge, Massachusetts-based Biogen said distribution of Tysabri > for Crohn's patients will begin by the end of next month. Company > representatives said a year's supply of drug will likely be priced at > $29,000 (euro19,470).> > Last week, Biogen management said it hoped to expand Tysabri's market > to 100,000 patients by 2010. But some analysts, including BMO Capital > Markets Zhang, note the drug's safety risks could limit its > distribution.> > The drug is expected to compete with Remicade in the U.S., the > leading Crohn's treatment made by and .>

_____________________________________________________________Extend the life of your truck's cargo area with a long lasting bed liner. Click now!